Literature DB >> 2999307

Production of a monoclonal antibody against an epitope on HeLa cells that is the functional poliovirus binding site.

P Nobis, R Zibirre, G Meyer, J Kühne, G Warnecke, G Koch.   

Abstract

Cell lines of primate origin carry receptors on their plasma membrane which are responsible for the specific binding of poliovirus. This paper describes the isolation and characterization of a monoclonal antibody reacting with the plasma membrane of HeLa cells. The antibody (D171) was selected for its protection of HeLa cells against the cytopathic effect of poliovirus type 1. This protection was found to extend to all three viral serotypes, while the replication of five other viruses in HeLa cells was not affected. The 125I-labelled purified antibody did not react with cell lines derived from pig, dog or rodents but bound specifically to all lines of human or primate origin. Immunoglobulin or Fab fragments of D171 prevented the binding of 35S-labelled poliovirus to HeLa cells. Conversely, nearly all binding sites of 125I-labelled D171 immunoglobulins or Fab fragments could be blocked after preincubation of HeLa cells with poliovirus. These results indicate that D171 recognizes the poliovirus receptor site on different susceptible cells and that practically all D171 binding sites are involved in the specific attachment of poliovirus to the plasma membrane. To determine whether the epitope recognized by D171 could be separated from the receptor for poliovirus, human-mouse cell hybrids were prepared and analysed. In all 40 clones tested, the susceptibility to poliovirus correlated with the binding of D171.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2999307     DOI: 10.1099/0022-1317-66-12-2563

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  39 in total

1.  A chimeric poliovirus/CD4 receptor confers susceptibility to poliovirus on mouse cells.

Authors:  H C Selinka; A Zibert; E Wimmer
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  Mutational analysis of the cellular receptor for poliovirus.

Authors:  M S Freistadt; V R Racaniello
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

3.  Functional domains of the poliovirus receptor.

Authors:  S Koike; I Ise; A Nomoto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

Review 4.  Strategies for the identification of icosahedral virus receptors.

Authors:  D M Bass; H B Greenberg
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

5.  A monoclonal antibody that blocks poliovirus attachment recognizes the lymphocyte homing receptor CD44.

Authors:  M P Shepley; V R Racaniello
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  Giardiavirus-resistant Giardia lamblia lacks a virus receptor on the cell membrane surface.

Authors:  T Sepp; A L Wang; C C Wang
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  Heterogeneous expression of poliovirus receptor-related proteins in human cells and tissues.

Authors:  M S Freistadt; G Kaplan; V R Racaniello
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

8.  Selective cleavage by trypsin of the capsid protein VP1 of type 3 poliovirus results in improved sorting of cell bound virions.

Authors:  L Piirainen; A Airaksinen; T Hovi; M Roivainen
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

9.  Overexpression of CD155 relates to metastasis and invasion in osteosarcoma.

Authors:  Baobiao Zhuo; Yuan Li; Feng Gu; Zhengwei Li; Qingzeng Sun; Yingchun Shi; Yang Shen; Fengfei Zhang; Rong Wang; Xiaodong Wang
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

10.  Polymorphisms of the hepatitis A virus cellular receptor 1 in African green monkey kidney cells result in antigenic variants that do not react with protective monoclonal antibody 190/4.

Authors:  D Feigelstock; P Thompson; P Mattoo; G G Kaplan
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.